Evidence map›Paper›PMID 31267315›Full record

ArticleJournal of molecular neuroscience : MN2019

Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?

Polyxeni Stamati, Vasileios Siokas, Athina-Maria Aloizou, Emmanouil Karampinis, Stylianos Arseniou, Valerii N Rakitskii, Aristidis Tsatsakis, Demetrios A Spandidos, Illana Gozes, Panayiotis D Mitsias and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Polyxeni StamatiDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.
Vasileios SiokasDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.
Athina-Maria AloizouDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.
Emmanouil KarampinisDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.
Stylianos ArseniouDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.
Valerii N RakitskiiThe Federal Budgetary Establishment of Science "Federal Scientific Center of Hygiene named after F. F. Erisman" of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 2 Semashko Street, Mytishchi, Moscow Oblast, Russian Federation, 141014.
Aristidis TsatsakisLaboratory of Toxicology, School of Medicine, University of Crete, 71003, Heraklion, Greece.
Demetrios A SpandidosLaboratory of Clinical Virology, Medical School, University of Crete, 71409, Heraklion, Greece.
Illana GozesThe Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, 69978, Tel Aviv, Israel.
Panayiotis D MitsiasDepartment of Neurology, School of Medicine, University of Crete, 71003, Heraklion, Greece.
Dimitrios P BogdanosDepartment of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Viopolis, 40500, Larissa, Greece.
Georgios M HadjigeorgiouDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.
Efthimios DardiotisDepartment of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece. edar@med.uth.gr.ORCID http://orcid.org/0000-0003-2957-641X

Funding

This study was supported in part by a research grant from the Research Committee of the University of Thessaly, Greece (code: 5287). This study was supported in part by a research grant from the Research Committee of the University of Thessaly, Greece (code: 5287).
6 · The paper itself

Abstract

Α number of genetic variants have been associated with Alzheimer's disease (AD) susceptibility. Sec1 family domain-containing protein 1 (SCFD1) gene polymorphism rs10139154 has recently been implicated in the risk of developing amyotrophic lateral sclerosis (ALS). Similarities in the pathogenetic cascade of both diseases have also been described. The present study was designed to evaluate the possible contribution of SCFD1 rs10139154 to AD. A total of 327 patients with AD and an equal number of healthy controls were included in the study and genotyped for rs10139154. With logistic regression analyses, rs10139154 was examined for the association with the risk of developing AD. In the recessive mode, SCFD1 rs10139154 was associated with a decreased risk of developing AD (odds ratio (OR) (95% confidence interval (CI)) = 0.63 (0.40-0.97), p = 0.036). The current study provides preliminary evidence of the involvement of SCFD1 rs10139154 in the risk of developing AD.

Indexed as

Polymorphism, Single NucleotideAdaptor Proteins, Vesicular TransportAgedAged, 80 and overAlzheimer DiseaseFemaleHumansMaleAdaptor Proteins, Vesicular TransportSCFD1 protein, humanADGeneticsPolymorphismSCFD1SNPs

Identifiers

PMID31267315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.